The Motley Fool

Stock market recovery: I’d buy these 5 FTSE 100 shares today to achieve financial freedom

Image source: Getty Images

We are still only in the early stages of the post-coronavirus stock market recovery. With the FTSE 100 standing at 6350, it is more than 1,000 points below its 2020 starting position. This leaves plenty of scope for growth in 2021, provided those vaccines work.

I’m under no illusions, the stock market recovery will be bumpy. Millions of jobs are surviving on government support. When furlough ends in the spring, we are likely to face an unemployment shock. That will feed into the rest of the economy. At times, 2021 could feel much worse than this year.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Despite these concerns, I’m still buying shares today, because my investment horizon is a minimum 15 years, not the next 15 months. Over such a lengthy period, I believe UK shares will beat almost every other asset class, as they have done in the past. You have to choose wisely, though, to maximise your returns. 

The FTSE 100 is fighting back

When picking out five FTSE 100 shares to play the stock market recovery, my first thought was to buy an airline. My second thought was it’s too risky, as their debts continue to mount. I have therefore plucked a stock from another embattled sector, banking. My choice here is Barclays, which has a diversified income stream, with its investment bank doing particularly well lately. Crucially, it is also well capitalised. Strict post-financial crisis regulation has served the banking sector well.

Next, I would buy household goods giant Unilever. Frankly, I haven’t seen a time when I wouldn’t buy this FTSE 100 stock, which enjoys strong demand for its range of branded products. I’m expecting steady capital growth and dividend income over the years ahead.

I favour credit rating specialist Experian as another good long-term buy and hold, as it should benefit from growing global demand for its information services. Profits have been hit by the lockdown, and may stay low in the short term as banks carry out fewer credit checks with people reluctant to borrow. It’ll bounce back, though, and I’d buy it ahead of the next phase of the stock market recovery.

I’m buying now before the stock market recovery

This year has shown the importance of having exposure to the defensive healthcare sector, and here I would buy AstraZeneca. Its vaccine plans suffered a slight setback, but I’d take advantage of the subsequent share price dip. The AstraZeneca share price is actually down 10% in the last six months, but its long-term income and growth prospects look solid to me.

My final pick for the stock market recovery is Schroders. Any asset manager that can grind its way through a tough year like this one and still increase its assets under management deserves our respect.

Another attraction of these five FTSE 100 stocks is that with the exception of Barclays, all pay dividends (I’m sure Barclays will be back, shortly). Unilever yields 3.11%, Experian 1.40%, AstraZeneca 2.76%, and Schroders 3.52%. You can find higher yields but these look sustainable to me, with plenty of scope for progression, too. Now roll on the stock market recovery.

You might fancy this stock.

The high-calibre small-cap stock flying under the City’s radar

Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…

You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.

And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.

Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.

But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before!

Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge!

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended Barclays, Experian, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.